Partners HealthCare

Partners HealthCare 2017 Annual Report

Issue link:

Contents of this Issue


Page 8 of 49

Last fall, more than two decades of work by Brigham and Women's Hospital (BWH) researchers culminated in a discovery that could fundamentally change the way we treat the two leading causes of death in the United States. The anti-infl ammatory drug the researchers studied proved effective in reducing the risk of both cardiac events and cancer. The study, known as CANTOS (Canak- inumab Anti-infl ammatory Thrombosis Outcomes Study) and led by Paul M. Ridker, MD, Director of the BWH Center for Cardiovascular Disease Prevention, represented the collective efforts of 1,000 physicians worldwide. Together, they collected data from more than 10,000 patients with a history of heart attack and high levels of C-reactive protein (hs-CRP), an infl ammation marker. Landmark Study Yields New Approaches to Heart Disease, Cancer INNOVATION YIELDING IMPACT | 8

Articles in this issue

Links on this page

view archives of Partners HealthCare - Partners HealthCare 2017 Annual Report